Earnings Scheduled For February 21, 2023
Companies Reporting Before The Bell
• Sohu.com (NASDAQ:SOHU) is likely to report earnings for its fourth quarter.
Goldman Sachs Initiates Coverage On PTC Therapeutics with Sell Rating, Announces Price Target of $35
Goldman Sachs analyst Paul Choi initiates coverage on PTC Therapeutics (NASDAQ:PTCT) with a Sell rating and announces Price Target of $35.
Why Pinterest Shares Jumped Around 14%; Here Are 69 Biggest Movers From Friday
Gainers
Quanergy Systems, Inc. (NASDAQ: QNGY) jumped 153.9% to close at $3.30 on Friday.
PTC Therapeutics Gets $1B Funding From Blackstone, Shares Fall
PTC Therapeutics Inc (NASDAQ:PTCT) entered into a strategic financing collaboration with Blackstone Inc (NYSE:BX). As part of the collaboration, Blackstone Life Sciences and…
RBC Capital Maintains Sector Perform on PTC Therapeutics, Lowers Price Target to $46
RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform and lowers the price target from $60 to $46.
Credit Suisse Maintains Neutral on PTC Therapeutics, Lowers Price Target to $47
Credit Suisse analyst Judah Frommer maintains PTC Therapeutics (NASDAQ:PTCT) with a Neutral and lowers the price target from $55 to $47.
Earnings Scheduled For October 27, 2022
Companies Reporting Before The Bell
• Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million.
Reaction Is Overdone For PTC Therapeutics Pausing Huntington Trial Enrollment, Analyst Says
Earlier today, the FDA requested additional data to allow a 12-week portion of the Phase 2 PIVOT-HD study…
PTC Therapeutics To Present Clinical And Real-World Evidence On Translarna At The Annual Congress Of The World Muscle Society
PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that recent clinical trial and real-world evidence on the efficacy and safety of Translarna™ (ataluren) in patients with nonsense mutation Duchenne muscular
Jefferies Initiates Coverage On PTC Therapeutics with Buy Rating, Announces Price Target of $62
Jefferies analyst Kelly Shi initiates coverage on PTC Therapeutics (NASDAQ:PTCT) with a Buy rating and announces Price Target of $62.